Multi Drug Resistant <i>Escherichia coli</i>Superinfection in Patient with COVID-19  

作　　者：Zeinab Dayoub Leen Al Ani Murhaf Aljebeh Adeeb Darwisha Firas Al Khani Basem Battah Zeinab Dayoub;Leen Al Ani;Murhaf Aljebeh;Adeeb Darwisha;Firas Al Khani;Basem Battah(Department of Microbiology and Biochemistry, Faculty of Pharmacy, Syrian Private University (SPU), Daraa International Highway, Syria;Department of Nephrology, Shami Hospital, Damascus, Syria)

机构地区：[1]Department of Microbiology and Biochemistry, Faculty of Pharmacy, Syrian Private University (SPU), Daraa International Highway, Syria [2]Department of Nephrology, Shami Hospital, Damascus, Syria

出　　处：《Journal of Biosciences and Medicines》2021年第9期1-7,共7页生物科学与医学（英文）

摘　　要：<strong>Background: </strong>Coronavirus Disease 2019 (COVID-19) has infected millions people worldwide and is continuing to spread rapidly. Patients with COVID-19 may be superinfected with other microorganisms. The prevalence of bacterial superinfection among coronavirus patients is not well understood. <strong>Aim:</strong> The aim of presenting this case is to highlight the problem of Multi-Drug Resistant (MDR) bacterial infection in COVID-19 patients. <strong>Case Presentation: </strong>Here we reported a 46 years old patient with the previous history of <em>Escherichia coli </em>urinary tract infection. A few weeks later, the patient was recovered from COVID-19 infection and was treated with antiviral therapy until PCR results become negative. Meanwhile, the patients developed urinary tract infection with MDR <em>Escherichia coli</em> even resistant to imipenem and required a critical treatment. <strong>Conclusion: </strong>Our finding suggests that greater attention should be paid to coronavirus infection complications and prophylaxis use of antibiotics. In addition, more studies are required to better understand the risk factors which are responsible for the superinfection and emergence of drug-resistant strains during COVID-19 infection.<strong>Background: </strong>Coronavirus Disease 2019 (COVID-19) has infected millions people worldwide and is continuing to spread rapidly. Patients with COVID-19 may be superinfected with other microorganisms. The prevalence of bacterial superinfection among coronavirus patients is not well understood. <strong>Aim:</strong> The aim of presenting this case is to highlight the problem of Multi-Drug Resistant (MDR) bacterial infection in COVID-19 patients. <strong>Case Presentation: </strong>Here we reported a 46 years old patient with the previous history of <em>Escherichia coli </em>urinary tract infection. A few weeks later, the patient was recovered from COVID-19 infection and was treated with antiviral therapy until PCR results become negative. Meanwhile, the patients developed urinary tract infection with MDR <em>Escherichia coli</em> even resistant to imipenem and required a critical treatment. <strong>Conclusion: </strong>Our finding suggests that greater attention should be paid to coronavirus infection complications and prophylaxis use of antibiotics. In addition, more studies are required to better understand the risk factors which are responsible for the superinfection and emergence of drug-resistant strains during COVID-19 infection.

关 键 词：Bacterial Resistance SUPERINFECTION COVID-19 

分 类 号：R73[医药卫生—肿瘤]